STOCK TITAN
  1. Home
  2. Sec-filings
  3. GALT
  4. [Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity

GALT Form 4: Insider sales at $4.93 and $4.94

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Galectin Therapeutics (GALT) reported insider transactions by 10X Fund, L.P., 10X Capital Management, LLC, and Director James C. Czirr on 10/22/2025. The filing lists two open‑market sales: 20,000 shares at $4.93 and 30,000 shares at $4.94.

Following these sales, the reporting persons show 5,872,207 shares beneficially owned. The form indicates direct ownership for the reported balance and includes standard footnotes stating that certain parties may be deemed to have indirect beneficial ownership, with ownership disclaimed except to the extent of pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider 10X Fund, L.P., 10X Capital Management, LLC, CZIRR JAMES C
Role 10% Owner | 10% Owner | 10% Owner
Sold 50,000 shs ($247K)
Type Security Shares Price Value
Sale Common Stock 20,000 $4.93 $99K
Sale Common Stock 30,000 $4.94 $148K
Holdings After Transaction: Common Stock — 5,902,207 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
10X Fund, L.P.
(Last) (First) (Middle)
545 DUTCH VALLEY ROAD, N.E., SUITE A
(Street)
ATLANTA, GA 30324
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 S 20,000 D $4.93 5,902,207 D(1)
Common Stock 10/22/2025 S 30,000 D $4.94 5,872,207 D(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
10X Fund, L.P.
(Last) (First) (Middle)
545 DUTCH VALLEY ROAD, N.E., SUITE A
(Street)
ATLANTA, GA 30324
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
10X Capital Management, LLC
(Last) (First) (Middle)
545 DUTCH VALLEY ROAD, N.E., SUITE A
(Street)
ATLANTA, GA 30324
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
CZIRR JAMES C
(Last) (First) (Middle)
4908 SOUTH ASHTON COURT
(Street)
SPOKANE WA 99223
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP 10/23/2025
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC 10/23/2025
/s/ James C. Czirr, Individually 10/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions were disclosed for GALT?

Two sales on 10/22/2025: 20,000 shares at $4.93 and 30,000 shares at $4.94.

How many GALT shares are beneficially owned after the transactions?

The filing reports 5,872,207 shares beneficially owned following the transactions.

Who are the reporting persons on this GALT Form 4?

10X Fund, L.P., 10X Capital Management, LLC, and James C. Czirr (Director).

What was the transaction date for the GALT insider sales?

The sales occurred on 10/22/2025.

Were the reported holdings listed as directly owned?

Yes, the post‑transaction holdings are shown as Direct (D), with a footnote regarding potential indirect beneficial ownership and related disclaimers.

Did the filing indicate use of a Rule 10b5-1 trading plan?

The form includes the 10b5‑1 checkbox language, but the excerpt does not indicate that the box was checked.